ABT Stock: Abbott Laboratories Slides Near 52-Week Low as Selling Pressure Mounts

By TrendSpider Editor

Abbott Laboratories is trading at $105.98 on Friday, March 20, 2026, down 1.13% and hovering just above its 52-week low of $105.27, a level that represents critical technical support for the stock. With the 52-week high sitting at $139.05, ABT has shed significant ground over the past year, now trad

ABT Stock: Abbott Laboratories Slides Near 52-Week Low as Selling Pressure Mounts

Abbott Laboratories is trading at $105.98 on Friday, March 20, 2026, down 1.13% and hovering just above its 52-week low of $105.27, a level that represents critical technical support for the stock. With the 52-week high sitting at $139.05, ABT has shed significant ground over the past year, now trading more than 23% off that peak. The proximity to multi-year lows puts price action in sharp focus heading into the weekend session.

Key Drivers of the ABT Stock Move

The forward setup for ABT is precarious from a technical standpoint. The stock has been unable to hold Thursday's intraday range of $107.14 to $109.749, and the current price of $105.98 leaves only $0.71 of cushion above the 52-week low. For bulls, defending $105.27 on a closing basis into the weekend is the immediate priority. A failure to do so could open the door to further downside with limited near-term technical support visible on the chart. Traders should monitor whether Friday's close confirms a breakdown or a potential reversal at this historically significant level, particularly given that end-of-week positioning often amplifies volume and volatility near key technical thresholds.

ABT Seasonality

March historically marks the tail end of the first quarter, a period when large-cap healthcare names like Abbott can experience repositioning as institutional investors rebalance portfolios ahead of quarter-end. A move toward 52-week lows in this window can sometimes reflect forced selling or tax-loss harvesting activity rather than fundamental deterioration alone.

ABT Relative Performance

ABT's 1.13% decline today and its position near a 52-week low stand out within the broader healthcare sector, which typically draws defensive capital during periods of market uncertainty. While direct peer price data is not available in today's data set, ABT's current price of $105.98 representing a range compression from a 52-week high of $139.05 suggests the stock has meaningfully underperformed the broader large-cap healthcare group over the trailing twelve months. Investors comparing ABT to sector benchmarks will note that this degree of drawdown warrants close attention to whether sector-wide headwinds or company-specific factors are driving the relative weakness.